Navigation Links
Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM)
Date:11/30/2009

/IV) Graft versus Host Disease. ATIR(TM) thereby significantly improves the outcome of the transplant procedure. Moreover, it enables the use of a mismatched, related (haplo-identical) donor, thus providing virtually everyone with an immediately available donor and treatment, thereby addressing a high unmet medical need as patients eligible for an allogeneic transplantation but without a matched donor available in general have no treatment options left.

ATIR(TM) has been granted orphan drug designations from both the FDA and the EMEA.

About Kiadis Pharma

Kiadis Pharma is an oncology focused biopharmaceutical development company with cell based products in clinical development. The company develops products that offer novel treatment options for terminally ill cancer patients and address significant unmet medical needs. The key focus indication for Kiadis Pharma is limitations and complications of bone marrow transplantation procedures. Kiadis Pharma is located in Amsterdam, The Netherlands. For more information about Kiadis Pharma, please visit http://www.kiadis.com.

English release is provided by Kiadis Pharma. Equivalent translations are from a third party.

SOURCE Kiadis Pharma


'/>"/>
SOURCE Kiadis Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
2. Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA
3. EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
4. Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
5. Kiadis Pharma Appoints Dr. Maarten Egeler, MD PhD as Chief Medical Officer
6. Kiadis Pharma Reports ATIR(TM) Clinical Data, Further Supporting its Potential in Mismatched Bone Marrow Transplantations
7. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
8. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
11. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... A new research platform uses a ... tiny structures undergoing stress and heating, an ... designs for microelectronics and batteries., This new ... about how heating and the surface stress ... Researchers have discussed the merits of surface-stress ...
(Date:8/28/2014)... 2014  Next month, executives from clinical trial marketing firm ... beginning with Patient-Centered Clinical Trials 2014 , to be ... , September 4-5. Patient recruitment experts Bonnie A. ... will share insights on the benefits of employing an ... – from media to mobile apps – can be used ...
(Date:8/28/2014)... work by a Florida State University research team has ... your temperature, emit white light, and convert photon energy ... like a butterfly. , Biwu Ma, associate professor in ... FAMU-FSU College of Engineering, created the molecule in a ... discover that his creation has many other unique capabilities. ...
(Date:8/28/2014)... Boston, MA (PRWEB) August 28, 2014 ... of wholesale construction materials, selected SoundConnect ... of their cloud based audio and web conferencing ... configured to support PrimeSource’s employees’ needs. SoundConnect ... technologies. , PrimeSource Building Products will be ...
Breaking Biology Technology:New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3BBK Worldwide Leads Sessions at Key September Events 2Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 2PrimeSource Chooses SoundConnect as Collaboration Provider 2
... accurately while minimizing ... 6 During his annual,physical check-up in March, David Kelver,s ... the right one looked a bit swollen. The,doctor concluded, however, ... own, and sent him home. Several months later, Kelver, a ...
... showing that Microsoft SQL Server ... 1 petabyte., REDMOND, Wash., Nov. 6 ... management and business,intelligence platform, Microsoft SQL Server 2008, ... scale new heights in data warehousing,and transaction processing., ...
... at Rodman & Renshaw,10th Annual Healthcare Conference" issued on ... over PR Newswire, we are advised by a,representative of ... the first paragraph. Complete, corrected release follows:, , ... the development of microRNA-based diagnostics, announced today it,will present ...
Cached Biology Technology:Cancer Care of Western New York Becomes First Center in Western New York to Treat Cancer with RapidArc(TM) Radiotherapy Technology from Varian Medical Systems 2Cancer Care of Western New York Becomes First Center in Western New York to Treat Cancer with RapidArc(TM) Radiotherapy Technology from Varian Medical Systems 3Cancer Care of Western New York Becomes First Center in Western New York to Treat Cancer with RapidArc(TM) Radiotherapy Technology from Varian Medical Systems 4Could Database Software Help Cure Alzheimer's and Save the Earth? 2Could Database Software Help Cure Alzheimer's and Save the Earth? 3/C O R R E C T I O N -- Rosetta Genomics Ltd/ 2/C O R R E C T I O N -- Rosetta Genomics Ltd/ 3/C O R R E C T I O N -- Rosetta Genomics Ltd/ 4/C O R R E C T I O N -- Rosetta Genomics Ltd/ 5/C O R R E C T I O N -- Rosetta Genomics Ltd/ 6
(Date:9/1/2014)... a life without light. They emit echolocation sounds and use ... obstacles or prey. In their brains, they have a spatial ... researchers at Technische Universitt Mnchen (TUM) has shown for the ... , Closer objects appear larger , ... the number of activated neurons in its brain increases. As ...
(Date:8/31/2014)... highly infectious bacteria C. diff , that causes ... a team at the University of Leicester. , Using ... it is possible to identify the unique ,smell, of ... diagnosis of the condition., What is more, the Leicester ... strains of the disease simply from their smell ...
(Date:8/31/2014)... in Nature Climate Change , suggests that if ... not exceed, the global targets for total greenhouse gas (GHG) ... should all think carefully about the food we choose and ... world is just one of a number of actions that ... ensure there is enough food for all. , As ...
Breaking Biology News(10 mins):Zooming in for a safe flight 2Scientists develop 'electronic nose' for rapid detection of C. diff infection 2Changing global diets is vital to reducing climate change 2Changing global diets is vital to reducing climate change 3Changing global diets is vital to reducing climate change 4
... clear change in salinity has been detected in the ... global rainfall and evaporation cycle., In a paper published ... the Commonwealth Scientific and Industrial Research Organisation (CSIRO) and ... of salinity in the global ocean during the past ...
... scientists has found there has been a massive reduction in ... of Antarctica.,Comparing detailed measurements taken during the Australian Antarctic program,s ... back to 1970, scientists estimate there has been as much ... Antarctic Bottom Water, the cold dense water that drives global ...
... Berlin, Germany, May 21, 2012 IMPACT World+, ... methodology was launched today in Berlin, Germany during the ... Meeting. The event featured the results of this innovative ... experts and researchers from five countries., The production and ...
Cached Biology News:Earth's water cycle intensifying with atmospheric warming 2Latest Southern Ocean research shows continuing deep ocean change 2Latest Southern Ocean research shows continuing deep ocean change 3Launch of IMPACT World+ 2
Mouse monoclonal [6C3] to JAB1 ( Abpromise for all tested applications). entrezGeneID: 10987 SwissProtID: O15386...
Human TGF-beta RIIb Affinity Purified Polyclonal Ab...
Human FGF R2 (alpha isoforms) MAb (Clone 98706)...
dithiothreitol, sulfhydryl reducing agent, C4H10O2S2; MW: 154.24, 97% pure (minimum), CAS No: 27565-41-9, store at -20 C ...
Biology Products: